Stocks · News reference

Ultragenyx Pharmaceutical shares are trading higher after the company announced that the FDA granted accelerated approval for GENGLYCOS. Also, Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $96 to $103.

Aug 20, 2026, 11:43 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 12:53 PMBenzinga Newsdesk
JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80
JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $75 to $80.
Read original at benzinga
RARE
BenzingaAug 21, 2026, 12:48 PMBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74
Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $67 to $74.
Read original at benzinga
RARE
BenzingaAug 20, 2026, 7:46 PMBenzinga Newsdesk
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $81 to $83.
Read original at benzinga
RARE
BenzingaAug 20, 2026, 6:45 PMBenzinga Newsdesk
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58
Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $45 to $58.
Read original at benzinga
RARE